Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

Aggressive lymphoma: news on ASH 2014

verfasst von: Michael A. Fridrik

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

This article reviews the most important news at American Society of Hematology (ASH) 2014 for the clinician. A validated risk model for central nervous system (CNS) relapse after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) defined a low, intermediate, and a high risk group. The latter with a CNS-relapse risk of 12 %. Interim positron emission tomography (PET) imaging and different treatment strategies for positive disease were highly prognostic for an unfavorable prognosis. However, the salvage strategies for these patients were not successful. The role of radiotherapy was clarified in a randomized trial of non-bulky stage I or II disease. It was not possible to demonstrate an event-free (EFS) and overall (OS) survival benefit for radiation after 4–6 R-CHOP cycles. Unfortunately ofatumomab was not superior to rituximab in combination with DHAP in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Literatur
1.
Zurück zum Zitat Savage KJ, Zeynalova S, Kansara RR, Nickelsen M, Villa D, Sehn LH, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. 2014. Savage KJ, Zeynalova S, Kansara RR, Nickelsen M, Villa D, Sehn LH, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. 2014.
2.
Zurück zum Zitat Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke Jr, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). 2014. Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke Jr, Mesters R, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas—a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). 2014.
3.
Zurück zum Zitat Sehn LH, Hardy ELG, Gill KK, Al-Tourah AJ, Shustik J, Macpherson NA, et al. Phase 2 trial of interim pet scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). 2014. Sehn LH, Hardy ELG, Gill KK, Al-Tourah AJ, Shustik J, Macpherson NA, et al. Phase 2 trial of interim pet scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). 2014.
4.
Zurück zum Zitat Lamy T, Damaj G, Gyan E, Soubeyran P, Bouabdallah K, Cartron G, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02–03 trial from the Lysa/Goelams group. 2014. Lamy T, Damaj G, Gyan E, Soubeyran P, Bouabdallah K, Cartron G, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02–03 trial from the Lysa/Goelams group. 2014.
5.
Zurück zum Zitat van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928). 2014. van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928). 2014.
Metadaten
Titel
Aggressive lymphoma: news on ASH 2014
verfasst von
Michael A. Fridrik
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0220-x

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe